Royal Bank of Canada
ENTA icon

Royal Bank of Canada’s Enanta Pharmaceuticals ENTA Stock Holding History

Royal Bank of Canada’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
110
-770
-88% -$10.3K ﹤0.01% 6858
2025
Q4 		$13K Sell
880
-301
-25% -$3.82K ﹤0.01% 6281
2025
Q3 		$14K Sell
1,181
-1,521
-56% -$12.2K ﹤0.01% 6360
2025
Q2 		$21K Buy
2,702
+299
+12% +$1.8K ﹤0.01% 6241
2025
Q1 		$13K Sell
2,403
-218
-8% -$1.35K ﹤0.01% 6058
2024
Q4 		$16K Buy
2,621
+465
+22% +$4.46K ﹤0.01% 6194
2024
Q3 		$22K Buy
2,156
+177
+9% +$2.31K ﹤0.01% 6066
2024
Q2 		$26K Buy
1,979
+1,435
+264% +$19.4K ﹤0.01% 5943
2024
Q1 		$10K Sell
544
-6,147
-92% -$81.3K ﹤0.01% 6197
2023
Q4 		$63K Buy
6,691
+2,975
+80% +$27.7K ﹤0.01% 5882
2023
Q3 		$41K Buy
3,716
+1,051
+39% +$16.9K ﹤0.01% 5878
2023
Q2 		$57K Buy
2,665
+1,085
+69% +$32K ﹤0.01% 5710
2023
Q1 		$64K Sell
1,580
-1,777
-53% -$84.9K ﹤0.01% 5480
2022
Q4 		$156K Buy
3,357
+2,652
+376% +$121K ﹤0.01% 5095
2022
Q3 		$36K Buy
705
+128
+22% +$7.48K ﹤0.01% 5899
2022
Q2 		$27K Sell
577
-1,091
-65% -$59.2K ﹤0.01% 5972
2022
Q1 		$119K Sell
1,668
-1,988
-54% -$129K ﹤0.01% 5519
2021
Q4 		$274K Buy
3,656
+1,236
+51% +$97K ﹤0.01% 5029
2021
Q3 		$138K Buy
2,420
+1,011
+72% +$50K ﹤0.01% 5476
2021
Q2 		$62K Buy
1,409
+1,313
+1,368% +$64.3K ﹤0.01% 5890
2021
Q1 		$4K Sell
96
-4,928
-98% -$246K ﹤0.01% 7094
2020
Q4 		$212K Sell
5,024
-552
-10% -$24.3K ﹤0.01% 4815
2020
Q3 		$255K Buy
5,576
+908
+19% +$44K ﹤0.01% 4366
2020
Q2 		$234K Sell
4,668
-285
-6% -$14.7K ﹤0.01% 4338
2020
Q1 		$255K Buy
4,953
+4,861
+5,284% +$259K ﹤0.01% 4154
2019
Q4 		$6K Sell
92
-36
-28% -$2.23K ﹤0.01% 6290
2019
Q3 		$7K Sell
128
-162
-56% -$12K ﹤0.01% 5889
2019
Q2 		$24K Hold
290
– – ﹤0.01% 5618
2019
Q1 		$28K Hold
290
– – ﹤0.01% 5483
2018
Q4 		$21K Sell
290
-54
-16% -$4.14K ﹤0.01% 5568
2018
Q3 		$29K Sell
344
-2,230
-87% -$223K ﹤0.01% 5495
2018
Q2 		$298K Sell
2,574
-1,606
-38% -$160K ﹤0.01% 4168
2018
Q1 		$338K Buy
4,180
+115
+3% +$8.85K ﹤0.01% 3977
2017
Q4 		$239K Sell
4,065
-2,368
-37% -$119K ﹤0.01% 4307
2017
Q3 		$301K Buy
6,433
+202
+3% +$8.12K ﹤0.01% 4198
2017
Q2 		$224K Sell
6,231
-1,189
-16% -$38K ﹤0.01% 4288
2017
Q1 		$229K Buy
7,420
+6,286
+554% +$196K ﹤0.01% 4263
2016
Q4 		$38K Buy
1,134
+720
+174% +$20.6K ﹤0.01% 5416
2016
Q3 		$11K Sell
414
-17,831
-98% -$414K ﹤0.01% 5749
2016
Q2 		$402K Sell
18,245
-6,774
-27% -$177K ﹤0.01% 3873
2016
Q1 		$735K Buy
25,019
+5,659
+29% +$158K ﹤0.01% 3330
2015
Q4 		$640K Buy
19,360
+1,496
+8% +$48.8K ﹤0.01% 3528
2015
Q3 		$646K Buy
17,864
+563
+3% +$24.2K ﹤0.01% 3258
2015
Q2 		$778K Buy
17,301
+3,895
+29% +$152K ﹤0.01% 3150
2015
Q1 		$410K Buy
13,406
+6,296
+89% +$245K ﹤0.01% 3690
2014
Q4 		$362K Buy
7,110
+6,857
+2,710% +$307K ﹤0.01% 3887
2014
Q3 		$10K Buy
253
+3
+1% +$120 ﹤0.01% 5480
2014
Q2 		$11K Sell
250
-250
-50% -$9.54K ﹤0.01% 5369
2014
Q1 		$20K Sell
500
-195
-28% -$7.08K ﹤0.01% 5203
2013
Q4 		$19K Buy
+695
New +$16.8K ﹤0.01% 5273

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada's ENTA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Enanta Pharmaceuticals (ENTA) stake by 88% in Q1 2026, selling an estimated $10.3K and leaving 110 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6858.

Royal Bank of Canada first reported a position in ENTA in Q4 2013 and has held it in 50 quarters since. The position peaked at $778K in Q2 2015. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Royal Bank of Canada held 110 shares of Enanta Pharmaceuticals worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 770 Enanta Pharmaceuticals shares in Q1 2026, an estimated $10.3K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6858 holding.
  • Royal Bank of Canada first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's Enanta Pharmaceuticals position peaked at $778K in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.